Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer

Wang,Xinyan; Liu,Xiaoling; Dai,Huwei; Jia,Junmei

doi:10.3892/ol.2023.13983

Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer

Authors:
- Xinyan Wang
- Xiaoling Liu
- Huwei Dai
- Junmei Jia
View Affiliations

Affiliations: Department of Internal Medicine, The First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of VIP Medical Services, Shanxi Province Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China, Department of Internal Medicine, The Second Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030001 P.R. China, Department of Oncology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: July 28, 2023 https://doi.org/10.3892/ol.2023.13983
Article Number: 397
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy offers survival benefits for patients with advanced gastric cancer, but not all populations can benefit from immunotherapy. Good nutritional status is fundamental to a patient's immune function and may have an impact on the efficacy of immunotherapy. The present study aimed to investigate changes in prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI) and albumin‑globulin ratio (AGR) values before and after immunotherapy in patients with advanced gastric cancer. The study also aimed to determine the potential association of the aforementioned values with patient outcomes and prognosis. Body mass index (BMI), serum albumin, total protein, peripheral blood lymphocyte, neutrophil, carcinoembryonic antigen (CEA), carbohydrate antigen19‑9 (CA19‑9) and a‑fetoprotein (AFP) data were collected from 195 patients with advanced gastric cancer who underwent immunotherapy from January 2020 to October 2021. In addition, PNI, ALI and AGR values were calculated based on variables in blood collected from the patients within 3 days prior to immunotherapy and 3 weeks after immunotherapy. The results demonstrated that low PNI was associated with elevated CEA levels. Moreover, low ALI levels were associated with reduced BMI levels, elevated AFP levels, PD‑L1 negative and first‑line treatment. Comparison of responding and non‑responding groups revealed that patients who responded to immunotherapy had higher PNI and AGR values than patients who did not respond, both before and after treatment, but had lower CEA and CA19‑9 levels after treatment. Furthermore, in the non‑responding group, PNI and AGR values were decreased and CEA values were increased following treatment compared with those prior to treatment. The objective response and disease control rates were higher in the high PNI and AGR groups compared with the low PNI and AGR groups, respectively. Moreover, PNI and AGR were found to be independent predictors of the short‑term efficacy of immunotherapy for advanced gastric cancer, with cut‑off values of 47.18 and 1.29, respectively. Univariate analysis revealed that ALI was associated with the progression‑free survival (PFS) of patients, while multivariate analysis demonstrated that baseline PNI and AGR were independent predictors of PFS. In conclusion, tumor progression leads to a decline in the nutritional level of patients, and the present study indicated that effective immunotherapy may alleviate this deterioration to a certain extent. Furthermore, PNI and AGR exhibit potential in predicting the efficacy of immunotherapy and the prognosis of patients with advanced gastric cancer, and may exhibit potential as biomarkers in clinical practice.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Ricci AD, Rizzo A and Brandi G: DNA damage response alterations in gastric cancer: Knocking down a new wall. Future Oncol. 17:865–868. 2021. View Article : Google Scholar : PubMed/NCBI
3	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ricci AD, Rizzo A, Rojas Llimpe FL, Di Fabio F, De Biase D and Rihawi K: Novel HER2-directed treatments in advanced gastric carcinoma: AnotHER paradigm shift? Cancers (Basel). 13:16642021. View Article : Google Scholar : PubMed/NCBI
5	Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K and Kang YK: Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 19:1372–1384. 2018. View Article : Google Scholar : PubMed/NCBI
6	Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, et al: Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC-A randomized phase III Trial. J Clin Oncol. 34:443–451. 2016. View Article : Google Scholar : PubMed/NCBI
7	Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
8	Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 18:640–653. 2017. View Article : Google Scholar : PubMed/NCBI
9	Rihawi K, Ricci AD, Rizzo A, Brocchi S, Marasco G, Pastore LV, Llimpe FLR, Golfieri R and Renzulli M: Tumor-associated macrophages and inflammatory microenvironment in gastric cancer: Novel translational implications. Int J Mol Sci. 22:38052021. View Article : Google Scholar : PubMed/NCBI
10	Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13:9644422022. View Article : Google Scholar : PubMed/NCBI
11	Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, et al: Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: A systematic review and meta-analysis. Eur J Cancer. 177:175–185. 2022. View Article : Google Scholar : PubMed/NCBI
12	Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI
13	Guidi A, Violati M, Blasi M, Ferrari E, Luciani A, Codecà C and Ferrari D: Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: A case report. Tumori. 106:NP23–NP28. 2020. View Article : Google Scholar : PubMed/NCBI
14	Ding P, Guo H, Sun C, Yang P, Kim NH, Tian Y, Liu Y, Liu P, Li Y and Zhao Q: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: A prospective study. BMC Gastroenterol. 22:1212022. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Zhu JY, Zhou LN, Tang M, Chen MB and Tao M: Predicting the prognosis of gastric cancer by albumin/globulin ratio and the prognostic nutritional index. Nutr Cancer. 72:635–644. 2020. View Article : Google Scholar : PubMed/NCBI
16	Yin C, Toiyama Y, Okugawa Y, Omura Y, Kusunoki Y, Kusunoki K, Imaoka Y, Yasuda H, Ohi M and Kusunoki M: Clinical significance of advanced lung cancer inflammation index, a nutritional and inflammation index, in gastric cancer patients after surgical resection: A propensity score matching analysis. Clin Nutr. 40:1130–1136. 2021. View Article : Google Scholar : PubMed/NCBI
17	Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al: iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017. View Article : Google Scholar : PubMed/NCBI
18	Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
19	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al: Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
20	Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al: The Chinese society of clinical oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 41:747–795. 2021. View Article : Google Scholar : PubMed/NCBI
21	Bossi P, Delrio P, Mascheroni A and Zanetti M: The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: A narrative review. Nutrients. 13:19802021. View Article : Google Scholar : PubMed/NCBI
22	Onodera T, Goseki N and Kosaki G: Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 85:1001–1005. 1984.(In Japanese). PubMed/NCBI
23	Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M and Baba H: Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg. 271:693–700. 2020. View Article : Google Scholar : PubMed/NCBI
24	Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z and Zhou L: Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC. J Gastrointest Surg. 25:421–427. 2021. View Article : Google Scholar : PubMed/NCBI
25	Shen F, Ma Y, Guo W and Li F: Prognostic value of geriatric nutritional risk index for patients with non-small cell lung cancer: A systematic review and meta-analysis. Lung. 200:661–669. 2022. View Article : Google Scholar : PubMed/NCBI
26	Nogueiro J, Santos-Sousa H, Pereira A, Devezas V, Fernandes C, Sousa F, Fonseca T, Barbosa E and Barbosa JA: The impact of the prognostic nutritional index (PNI) in gastric cancer. Langenbecks Arch Surg. 407:2703–2714. 2022. View Article : Google Scholar : PubMed/NCBI
27	Matsubara T, Takamori S, Haratake N, Toyozawa R, Miura N, Shimokawa M, Yamaguchi M, Seto T and Takenoyama M: The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J Thorac Dis. 12:1520–1528. 2020. View Article : Google Scholar : PubMed/NCBI
28	Guven DC, Aktepe OH, Taban H, Aktas BY, Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, et al: Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Biomark Med. 15:1123–1130. 2021. View Article : Google Scholar : PubMed/NCBI
29	Ishiyama Y, Kondo T, Nemoto Y, Kobari Y, Ishihara H, Tachibana H, Yoshida K, Hashimoto Y, Takagi T, Iizuka J and Tanabe K: Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. Anticancer Res. 41:1607–1614. 2021. View Article : Google Scholar : PubMed/NCBI
30	Song M, Zhang Q, Song C, Liu T, Zhang X, Ruan G, Tang M, Xie H, Zhang H, Ge Y, et al: The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer. J Cachexia Sarcopenia Muscle. 13:2504–2514. 2022. View Article : Google Scholar : PubMed/NCBI
31	Wu H, Ding F, Lin M, Shi Z, Mei Z, Chen S, Jiang C, Qiu H, Zheng Z, Chen Y and Zhao P: Use of the advanced lung cancer inflammation index as a prognostic indicator for patients with cholangiocarcinoma. Front Surg. 9:8017672022. View Article : Google Scholar : PubMed/NCBI
32	Gaudioso P, Borsetto D, Tirelli G, Tofanelli M, Cragnolini F, Menegaldo A, Fabbris C, Molteni G, Marchioni D, Nicolai P, et al: Advanced lung cancer inflammation index and its prognostic value in HPV-negative head and neck squamous cell carcinoma: A multicentre study. Support Care Cancer. 29:4683–4691. 2021. View Article : Google Scholar : PubMed/NCBI
33	Pian G, Hong SY and Oh SY: Prognostic value of advanced lung cancer inflammation index in patients with colorectal cancer liver metastases undergoing surgery. Tumori. 108:56–62. 2022. View Article : Google Scholar : PubMed/NCBI
34	Zhang X, Wang D, Sun T, Li W and Dang C: Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection. BMC Cancer. 22:6842022. View Article : Google Scholar : PubMed/NCBI
35	Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et al: Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 6:1002542021. View Article : Google Scholar : PubMed/NCBI
36	Guven DC, Aktepe OH, Aksun MS, Sahin TK, Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, et al: The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. Cancer Biomark. 34:189–199. 2022. View Article : Google Scholar : PubMed/NCBI
37	Hill LA, Bodnar TS, Weinberg J and Hammond GL: Corticosteroid-binding globulin is a biomarker of inflammation onset and severity in female rats. J Endocrinol. 230:215–225. 2016. View Article : Google Scholar : PubMed/NCBI
38	Bae YJ and Kratzsch J: Corticosteroid-binding globulin: Modulating mechanisms of bioavailability of cortisol and its clinical implications. Best Pract Res Clin Endocrinol Metab. 29:761–772. 2015. View Article : Google Scholar : PubMed/NCBI
39	Xie HL, Zhang Q, Ruan GT, Ge YZ, Hu CL, Song MM, Song CH, Zhang X, Zhang XW, Li XR, et al: Evaluation and validation of the prognostic value of serum albumin to globulin ratio in patients with cancer cachexia: Results from a large multicenter collaboration. Front Oncol. 11:7077052021. View Article : Google Scholar : PubMed/NCBI
40	Salciccia S, Frisenda M, Bevilacqua G, Viscuso P, Casale P, De Berardinis E, Di Pierro GB, Cattarino S, Giorgino G, Rosati D, et al: Prognostic value of albumin to globulin ratio in non-metastatic and metastatic prostate cancer patients: A meta-analysis and systematic review. Int J Mol Sci. 23:115012022. View Article : Google Scholar : PubMed/NCBI
41	Rong G, Liu S, Xi C, Wang C, Deng J and Qin T: Correlation between preoperative serum albumin-globulin ratio and prognosis of patients undergoing low rectal cancer surgery. Clin Lab. 68:2022. View Article : Google Scholar : PubMed/NCBI
42	Oymak E, Guler OC and Onal C: Prognostic significance of albumin and globulin levels in cervical cancer patients treated with chemoradiotherapy. Int J Gynecol Cancer. 33:19–25. 2023. View Article : Google Scholar : PubMed/NCBI
43	Gundog M and Basaran H: Pretreatment low prognostic nutritional index and low albumin-globulin ratio are predictive for overall survival in nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 276:3221–3230. 2019. View Article : Google Scholar : PubMed/NCBI
44	Liu C, Wang W, Meng X, Sun B, Cong Y, Liu J, Wang Q, Liu G and Wu S: Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients. Onco Targets Ther. 11:2131–2139. 2018. View Article : Google Scholar : PubMed/NCBI
45	Lv GY, An L, Sun XD, Hu YL and Sun DW: Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: A meta-analysis. Clin Chim Acta. 476:81–91. 2018. View Article : Google Scholar : PubMed/NCBI